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Abstract
Vitamin K antagonists (VKAs) are effective oral anticoagulants that are titrated to a narrow therapeutic international
normalized ratio (INR) range. We reviewed published literature assessing the impact of INR stability - getting into
and staying in target INR range - on outcomes including thrombotic events, major bleeding, and treatment costs,
as well as key factors that impact INR stability.
A time in therapeutic range (TTR) of ≥65 % is commonly accepted as the definition of INR stability. In the
real-world setting, this is seldom achieved with standard-of-care management, thus increasing the patients’ risks of
thrombotic or major bleeding events. There are many factors associated with poor INR control. Being treated in
community settings, newly initiated on a VKA, younger in age, or nonadherent to therapy, as well as having
polymorphisms of CYP2C9 or VKORC1, or multiple physical or mental co-morbid disease states have been
associated with lower TTR. Clinical prediction tools are available, though they can only explain <10 % of the
variance behind poor INR control.
Clinicians caring for patients who require anticoagulation are encouraged to intensify diligence in INR management
when using VKAs and to consider appropriate use of newer anticoagulants as a therapeutic option.
Keywords: Vitamin K antagonists, International normalized ratio, Anticoagulation, Atrial fibrillation, Venous
thromboembolism
Background
Vitamin K antagonists (VKAs) such as warfarin inhibit
the enzyme vitamin K epoxide reductase and conse-
quently the recycling of inactive vitamin K epoxide back
to its active, reduced form [1]. Vitamin K in its active
form is required for the synthesis of various clotting
factors (II, VII, IX and X) involved in the coagulation
cascade (as well as the anti-clotting proteins C and S);
and thus, VKAs result in the depletion of these factors
(within 72–96 h after dosing) and an anticoagulated
state.
VKAs are indicated for the prevention of thrombotic
events in patients with atrial fibrillation (AF) and follow-
ing venous thromboembolism (VTE) [2, 3]. For stroke
prevention in AF patients, VKA therapy that is dose-
adjusted to maintain an international normalized ratio
(INR) range of 2.0 to 3.0 is associated with a 64 %
reduction in the risk of stroke compared to placebo [4].
In patients suffering an acute VTE (either deep vein
thrombosis (DVT) or pulmonary embolism (PE)),
adjusted-dose VKA use (preceded by a parenteral anti-
coagulant) significantly reduces the risk of recurrence of
thrombotic events [3, 5, 6]. Adjusted-dose VKAs are
included in clinical guidelines for AF and VTE [2, 3, 7, 8]
with a target INR range of 2.0–3.0.
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The objective of this paper is to provide an assessment
of “INR stability” with VKA use and patient outcomes in
contemporary practice. INR stability refers to achieving
and maintaining target INR range (typically 2–3, but not
always). Therefore, if target INR range is not achieved or
maintained this would be considered INR instability.
We will determine: 1) to what extent INR instability
can be anticipated, 2) whether INR instability is predict-
able, and 3) the consequences of INR instability.
Metrics of INR
Despite 60 years of clinical experience, the maintenance
of stable INR in patients using VKA remains a challen-
ging task. While numerous metrics have been used in
clinical studies of VKAs to assess the quality of anticoa-
gulation control [9, 10], time in therapeutic range (TTR)
(most commonly calculated using Rosendaal’s method of
linear interpolation [11]) is the most frequently reported.
Experts have suggested that the minimum target TTR
should be no less than 65 % [12–15] but this goal is
often not met [16–22] even in modern day RCTs
[23–32] (Table 1). A large observational assessment of
40,404 patients in the VA population demonstrated
that 42 % of patients had INR stability (defined as
TTR > 70 %) while 34 % had moderate instability
(TTR 50 to 70 %), and 23 % had high instability
(TTR <50 %) [33]. A recently published retrospective
analysis from the CoagClinic™ database assessed 9433
patients who met the inclusion criteria and had been
using warfarin for over 6 months [34]. In these
chronic warfarin patients, more than 90 % had at
least one value below 2 and 82 % had at least one
value above 3 (Fig. 1).
Using data from the multicenter ORBIT-AF (Outcomes
Registry for Better Informed Treatment of Atrial
Fibrillation) registry, the INR stability of 3749 patients
on chronic warfarin therapy for 6 months was assessed
[35]. Only 26 % (95%CI: 24 to 27 %) of patients had 80 %
or more of their INRs between 2 and 3. Among this sub-
group with INR stability, 92 % (95%CI: 90 to 94 %) had at
least one value outside of the normal INR range while
36 % (95%CI: 33 to 39 %) had an INR below 1.5 or above
4 over the subsequent year. Thus, even the “cream of the
crop” – those patients able to achieve most of their values
within target range within a 6-month period – had at
least occasional out-of-range values over longer-term
follow-up.
Multiple meta-analyses of randomized and real-world
studies have been performed in order to estimate the
quality of INR control in AF and VTE populations re-
ceiving VKAs [16–20, 22]. These meta-analyses dem-
onstrate poor INR control to be ‘the rule rather than
the exception’ with TTRs and proportion of INR
measurement in range typically falling near or below
60 % and nearly twice the amount of time being
spent below versus above the therapeutic INR range
(Table 2) [16–20, 22].
The literature from clinical trials and observational
studies substantiate that INR stability is not readily at-
tainable and when it occurs, is rarely sustainable over
time.
Consequences of INR Instability
Outcomes
The consequences of INR instability are multifaceted.
INR instability was associated with clinical events, higher
level of medication non-persistence and discontinuation,
utilization of more healthcare resources, and therefore,
higher costs. According to meta-analyses of AF or mixed
populations assessing INR control and associated events
[18, 36–38], greater than half of all thromboembolic
events occurred when patients have an INR < 2.0, while
Table 1 Mean time in the therapeutic range observed in recent atrial fibrillation and venous thromboembolism randomized
controlled trials of novel target oral anticoagulants
Study Disease state Mean TTR TTR in month 1a TTR in later monthsa
ARISTOTLE NVAF 62 %
ENGAGE-TIMI-48 2013 NVAF 65 %
RE-LY 2009 NVAF 64 %
ROCKET-AF, 2010 NVAF 55 %
AMPLIFY VTE 61 % NR NR
EINSTEIN-DVT DVT 58 % 54 % 66 % (month 10)
EINSTEIN-PE PE 63 % 58 % 73 % (month 11)
Hokusai-VTE VTE 64 % NR NR
RECOVER 1 VTE 60 % 53 % 66 % (month 6)
RECOVER 2 VTE 57 % 51 % 54–62 % (months 3–6)
DVT deep vein thrombosis, NR not reported, NVAF nonvalvular atrial fibrillation, PE pulmonary embolism, TTR time in the therapeutic range, VTE
venous thromboembolism
aFor venous thromboembolism studies only
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over 40 % of all hemorrhagic events occurred at an
INR >3.0. In VTE patients, subtherapeutic INRs were
found to be present during 58 % of recurrent VTEs [17].
An observational study by Nelson et al, [38] using the
Veterans Health Administration (VHA) dataset, explored
the relationship between out-of-range INRs and clinical
outcomes in 34,346 patients with non-valvular AF (NVAF)
who were newly initiated on warfarin therapy. When INR
values were below range (<2), patients were much more
likely to experience adverse thrombotic or embolic events
(Fig. 2). Patients were at an increased risk of major
bleeding with both subtherapeutic INR values (RR = 2.58
95%CI: 2.19–3.03) as well as supratherapeutic INR values,
(RR = 1.55, 95%CI: 1.21–1.97). All event rates were
qualitatively the highest when patients had an INR < 2.
While most of these events were stroke associated
with sub-therapeutic values, increased bleeding events
were also observed. While only speculative (and we
could not identify supportive literature) it is possible
the increased bleeding associated with sub-therapeutic
INRs is due a lag in time between the actual event
and the true INR value. This emphasizes the need for
Fig. 1 Percent of patients with ≥1 INRs outside the normal therapeutic range. This figure displays the % of people in an analysis [34] of the
CoagCheckTM database with at least one INR value outside of the normal therapeutic range with blue boxes showing the percent of patients
who were either below 2.0 (90 %) or above 3.0 (82 %). The red, green, purple, and orange boxes display the percent of people who ever
achieved a level of 3.0–4.0, 4.0–5.0, 5.0–6.0, and >6.0, respectively. The same individual could be represented in multiple categories given their
INRs achieved over time including being below 2.0 and above 3.0
Table 2 Results of meta-analyses evaluating the international normalized ratio stability in atrial fibrillation or venous thromboembol-
ism patients












Mearns 2014 AF 61 (59 to 62) 25 (23 to 27) 14 (13 to 15) 59 (53 to 59) 26 (23 to 29) 13 (11 to 17)
Mearns 2014 VTE 61 (59 to 63) 25 (23 to 26) 15 (14 to 17) 59 (54 to 64) 26 (23 to 29) 13 (9 to 19)
Erkens 2012 (Month 1) VTE 54 (NR) 42 (NR) 12 (NR) NR NR NR
Erkens 2012 (Months 1–3) 56 (NR) 35 (NR) 19 (NR) NR NR NR
Erkens 2012 (Month 1–6+) 60 (NR) 24 (NR) 17 (NR) NR NR NR
Erkens 2012 (Month 4–12+) 75 (NR) 21 (NR) 12 (NR) NR NR NR
Wan 2008 (RCT) AF 67 (44 to 73) 20 (18 t to 40) 14 (9 to 17) 67 (48 to 84) 24 (14 to 32) 8 (2 to 24)
Wan 2008 (Prospective) 61 (56 to 66) 21 (14 to 29) 14 (13 to 30) — — —
Wan 2008 (Retrospective) 59 (29 to 75) 25 (9 to 52) 14 (9 to 39) 53 (34 to 68) 26 (10 to 51) 17 (14 to 29)
Cios 2009 AF 59 (57 to 61) NR NR NR NR NR
Reynolds 2004 AF 61 (NR) 26 (NR) 13 (NR) 61 (NR) 25 (NR) 14 (NR)
AF atrial fibrillation, CI confidence interval, NR not reported, PINRAR proportion of INRs above range, PINRBR proportion of INRs below range, PINRR proportion of
INRs in range; RCT randomized controlled trial, TAR time above range, TBR time below range, TTR time in range, VTE venous thromboembolism
— = evaluated, but no data
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close INR monitoring to prevent subtherapeutic war-
farin dosing.
Further evidence showed the link between INR in-
stability and clinical events. In meta-analyses that exam-
ine the relationship between TTR and the prediction of
adverse events, a significant negative relationship has
been observed [19]. In patients with AF, 1 thrombotic or
major hemorrhagic event per 100 patient-years could be
avoided by improving TTR by 7 % or 12 %, respectively
[19]. Likewise in patients with VTE, for every 1 % in-
crease in TTR, recurrent thromboembolic events may
be reduced by 0.46 % per year and major hemorrhagic
events reduced by 0.30 % [17]. Furthermore, in a nested
case control analysis of the Atrial fibrillation Clopidogrel
Trial with Irbesartan for prevention of Vascular Events
(ACTIVE W) study, patients who experienced an ische-
mic stroke had a TTR 9.5 % lower than those without
any ischemic event [39]. The TTR of patients with a
major hemorrhage was 7.2 % lower when compared to
those without an event, again, suggesting that TTR is a
useful predictor for both hemorrhagic and thrombo-
embolic events. Of note, ACTIVE W also found that
patients spent a greater amount of time out of range in
the 1–2 months preceding a major bleeding event or
stroke which suggests even a temporary period out of
range can lead to a bleeding event or stroke.
Inability to achieve high TTR in clinical practice is
associated with non-persistence and medication discon-
tinuation [40]. In an analysis of longitudinal anticoagula-
tion management records from 15,276 US patients with
NVAF, discontinuation of therapy occurred in less than
4 months among patients with unstable INR. Patients
who achieved INR stabilization were 10 times more
likely to remain on warfarin therapy beyond 1 year. In
another observational study using the Symphony Health
Solutions’ Patient Transactional Database, patients who
were prescribed rivaroxaban had a lower risk of treat-
ment nonpersistence [HR 0.66 (95%CI: 0.60–0.72)] com-
pared to patients who were prescribed warfarin [41]. A
similar analysis of the Truven Health Market Scan Re-
search Databases showed comparable findings, that
NVAF patients who received rivaroxaban were 46 % less
likely to discontinue therapy compared to those receiv-
ing warfarin [42]. Continued protection by anticoagula-
tion is particularly important for patients with NVAF,
since the risk of stroke is expected to increase with age
and additional comorbidities [43].
Costs
INR instability was associated with higher healthcare
utilization and costs. In an observational study using the
Premier Perspective Comparative Hospital Database,
hospital length of stay was 5.27 days vs. 4.46 days, lead-
ing to significant differences in hospitalization costs
($13,255 vs. $11,993, P < 0.001) [44, 45]. In another
comprehensive cost analysis of 23,588 patients with
NVAF who were on warfarin for at least 30 days from
the US Veteran’s Administration, investigators randomly
selected an INR value from a patient and classified it as
being below 2, 2–3, or above 3 and then evaluated total
direct costs (i.e. inpatient, outpatient medical, and out-
patient pharmacy costs) over the next 30 days. Mean
Fig. 2 Risks of adverse outcomes for people with INRs <2.0 or >3.0. Adapted from data from an observational study using the Veterans Health
Administration dataset [38] showing the relative risk (RR) of adverse thrombotic or embolic events in patients with subtherapeutic INRs versus
normal INRs and then major bleeding vents with supertherapeutic INRs versus normal INRs. The diamond represents the actual RR with the line
representing the 95 % confidence interval and the blue dashed line representing a RR of 1.0, where the risk of outcomes would have been the
same as those with normal INRs
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direct costs over 30-days after exposure to an INR <2.0,
between 2 and 3, and >3.0 were $5126, $2355 and $3419
(Fig. 3) [46]. These findings remained robust in a sensi-
tivity analysis with a more stringent definition of the co-
hort. The substantial cost difference between in-range
and out-of-range time is significant across a broad war-
farin population with atrial fibrillation.
The literature suggests that INR instability has import-
ant clinical and financial consequences which under-
score the need for greater vigilance on achieving INR
stability or the use of a novel oral anticoagulant which
provides more consistent pharmacologic effects.
Predicting INR Instability
Predictors
Based on data from adjusted meta-regression or multi-
variate analyses of large datasets, INR stability is known
to vary greatly based upon various study- and patient-
level factors (Table 3) [15–17, 21, 47, 48]. The use of
anticoagulation clinics can positively impact higher TTR
attainment but only ~1/3 of VKA patients have access to
these advanced services [49]. Therefore, a broad under-
standing of factors predicting INR instability is beneficial
for clinical practice.
Two of the most extensive studies were conducted by
Apostolakis et al. (SAMe-TT2R2) [14] and Rose et al.
(VARIA) [48] and provided insight into factors affecting
anticoagulation control. Apostolakis and colleagues [14]
used data from the 1061 patients in the Atrial Fibrillation
Follow-up Investigation of Rhythm Management (AFFIRM)
trial to identify clinical factors associated with TTR. Based
upon these results, the SAMe-TT2R2 score was derived
(and eventually validated) whereby 1 or 2 points are
assigned for important patient factors (Table 4). Scores ≥2
were found to be associated with decreased odds of achiev-
ing a TTR ≥65 % (previously described as the minimum
target TTR) [14].
The Veterans AffaiRs study to Improve Anticoagula-
tion (VARIA) [48] used data from over 124,000 veterans
receiving warfarin for any indication (55 % AF, 35 %
VTE, 10 % other) between 2006 and 2008; and evaluated
the effect of various patient characteristics on TTR in
those starting warfarin (first 6 months of therapy) and
who were experienced (on therapy for >6 months). Like
the SAMe-TT2R2 derivation/validation study, female
gender, younger age, minority status and co-morbid
physical conditions were also found to be associated
with lower TTR in VARIA (in both the inception or ex-
perienced cohorts) but there were a large number of
additional factors which were identified, such as alcohol
abuse, number of hospitalizations, and various comor-
bidities, such as heart failure, diabetes, chronic kidney
disease, and others. The VARIA investigators also
created a clinical prediction tool but eliminated race be-
cause they did not wish to perpetuate disparities in care,
eliminated poverty and distance to drive to receive care
because they felt it was hard to assess, and eliminated
other factors to simplify the model. Their model is avail-
able in a downloadable excel spreadsheet from Supple-
mental Appendix 3S at http://onlinelibrary.wiley.com/
doi/10.1111/j.1538-7836.2010.03996.x/full. In addition to
the factors in the SAMeTT2R2 score, this tool also
assesses the indication for use, total number of chronic
medications, substance abuse, mental illnesses, number
Fig. 3 Costs Associated with In Range and Out of Range INRs. Adapted from data from a US Veterans Administration dataset [46] where the
total costs are displayed in blue and the constituent costs of inpatient, outpatient, and outpatient pharmacy costs are in red, green, and purple,
respectively. The total costs in the therapeutic INR group is significantly lower than those with abnormally low or high INR groups. Note that the
highest costs were associated with suboptimal INR values (i.e., INR <2.0)
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of hospitalizations, and the general quality of TTR at-
tainment in other patients within that healthcare setting.
Even with all of these additional factors, the R-squared
value only ranged from 3.2 to 6.8 % suggesting that the
much of the variability in TTR is not explained by this
model. Furthermore, while the study assessed TTR at
therapy initiation and after chronic therapy, the authors
stated that the prediction tool is not to be used as a
means to assess long term control, and that clinical
experience from past VKA therapy is the preferred
method [48].
Factors that effect INR instability
Two reasons why the clinical prediction tools are in-
adequate may be related to genetics and adherence to
therapy. Patient genotype plays an important role in INR
stability [12, 50–52]. At least 30 genes contribute to the
anticoagulant effects of VKAs, with one third of the
variance in warfarin dosing related to mutations in
genes leading to the synthesis of CYP2C9 and vitamin
K epoxide reductase (VKORC1) [12, 50–52]. Patients
with CYP2C9*2 and CYP2C9*3 polymorphisms have
decreased enzymatic activity, metabolize warfarin (and
to a lesser extent acenocoumarol) more slowly, have a
1.4- to 3.6-fold increased risk of supratherapeutic
Table 4 SAMe-TT2R2 scoring system and implications
Criteria One point Two points Points
Sex Female gender 1
Age Age < 60 years old 1











Treatment Treatment with amiodarone 1
Tobacco Tobacco use in






The SAMe-TT2R2 score allows an initial patient assessment to discern who is
unlikely to achieve a TTR ≥65 %. Patients that score ≥ 2 have reduces odds of
achieving TTR ≥65 %. It does not include the risk associated with instability
after initiation, only the ability to achieve longer term control [17]
Table 3 Summative assessment of factors shown to positively or negatively impact INR stability
Factor Data source Significant factors the impact INR stability
Poorer INR Stability
VKA Use in Community Setting vs. Anticoagulation Clinic Meta-Regression ↓ TTR by 7.1 to 7.2 %
VKA Naïve vs. VKA-Experienced Meta-Regression ↓ TTR by 5.3 %
Heart Failure Multivariate Analysis OR 1.41 for TTR Instability
Diabetes Mellitus Multivariate Analysis OR 1.28 for TTR Instability
Stroke History Multivariate Analysis OR 1.15 for TTR Instability
Higher CHADS2 Score Multivariate Analysis ↓ TTR by 7.6 % (SAMe-TT2R2)
Female Gender Multivariate Analysis ↓ TTR by 6.0 % (SAMe-TT2R2)
Younger Age Multivariate Analysis ↓ TTR by 20.3 % Age <50 (SAMe-TT2R2)
↓ TTR by 7.7 % Age 50–60 (SAMe-TT2R2)
Minority Status Multivariate Analysis ↓ TTR by 18.5 % (SAMe-TT2R2)
Smoking Multivariate Analysis ↓ TTR by 10.8 % (SAMe-TT2R2)
Amiodarone Use Multivariate Analysis ↓ TTR by 7.7 % (SAMe-TT2R2)
Better INR Stability
VKA Self Management vs. No Self Management Meta-Regression ↑ TTR by 7.0 %
European/United Kingdom Treatment vs. Elsewhere Meta-Regression ↑ TTR by 9.7 %
Non-Warfarin VKAs vs. Warfarin Meta-Regression ↑ TTR by 9.2 %
Male Gender Multivariate Analysis OR 0.78 for TTR Instability
Hypertension Multivariate Analysis OR 0.86 for TTR Instability
Beta-Blocker Use Multivariate Analysis ↑TTR by 4.8 % (SAMe-TT2R2)
Verapamil Use Multivariate Analysis ↑ TTR by 6.3 % (SAMe-TT2R2)
OR Odds Ratio, TTR Time in Therapeutic Range, VKA Vitamin K Antagonist
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INR, and often take longer to achieve stable dosing
[53–55]. VKORC1 polymorphisms can result in either
a heightened (group A haplotype) or reduced effect
(group B haplotype) of warfarin which alters the risk
of thromboembolism and bleeding accordingly [12].
Based on this data, the Food and Drug Administration al-
tered the package insert recommending clinicians con-
sider genetic testing before initiating warfarin therapy
[56]. However, the cost-effectiveness of this approach is
questionable; with economic models suggesting genotyp-
ing of patients would cost more than $170,000 per AF
patient quality-adjusted life-year (QALY) gained (far above
the commonly accepted willingness-to-pay threshold of
$50,000 per QALY) [57].
Medication adherence was highlighted as an important
variable in VKA INR stability in the American College
of Chest Physicians (ACCP) guidelines [12]. Identified
predictors of VKA nonadherence include not being mar-
ried, not having a vehicle for transportation, education
levels beyond high school, currently employed, lower
levels of mental health functioning, poor cognitive func-
tioning, and greater drug regimen complexity [58, 59].
In addition, studies have identified patient dissatisfaction
with care as a cause of medication non-adherence in pa-
tients with cardiovascular disease states [60]. This is
noteworthy since patient satisfaction with warfarin ther-
apy has been shown to be poor in recent studies of AF
[61] and VTE patients [62]. In the above-mentioned
studies, poor patient satisfaction in either AF or VTE
patients (measure by the Anti-Clot Treatment Scale)
was related to the burden and frustration of taking
VKAs resulting from fear of bleeding/bruising, diet and
alcohol interactions and the perceived hassle of INR
monitoring. One of the frequently cited studies evaluat-
ing the association between VKA non-adherence and
INR control is the International Normalized Ratio
Adherence and Genetics (IN-RANGE) Study [63]. IN-
RANGE was a prospective cohort study conducted at
3 US anticoagulation clinics and assessed warfarin ad-
herence using a medication electronic monitoring sys-
tem (MEMS). The study followed 136 patients taking
warfarin for a variety of reasons (but predominantly
AF and VTE) for a mean of 32-weeks and found that
missed warfarin doses (missed MEMS bottle open-
ings) were common, with 92 % of patients missed at
least 1 dose, and one-third missed more than 20 % of
their doses. A total of 1490 INRs values were col-
lected, with 40 % out of range and 26 % being below
range. Upon multivariable regression analysis, re-
searchers found that for every 10 % increase in
missed warfarin doses (days without a dose), there
was a 14 % increase in the adjusted odds of under-
anticoagulation (having an INR < 2.0); and patients
who missed >20 % of their doses (missed 20 days of
warfarin therapy) had a 2.10-fold (95%CI: 1.48–2.96)
increase in their odds of having an INR < 2.0 [63].
Existing research provided good understanding of the
drivers behind poor INR control. The research findings
indicate that many of the patient factors are not modifi-
able and are also not sufficiently reliable to predict
whether VKA will perform well for a particular patient.
Modalities to optimize clinical management of VKAs
There are several modalities to improve the clinical
management of patients on VKAs including computer
assisted dosing and patient self-testing or management.
In a randomized study of 13,219 patients conducted in
32 centers around the world, the impact of software pro-
gram guided VKA therapy was compared with experi-
enced clinician dosing [64]. Unadjusted INR time in
range was 67 and 66 % with computer-assisted versus
experienced clinician dosing. However, in order to elicit
these comparable results, the experienced medical staff
randomized to use the computer assisted program pro-
vided 11 % of the dosages because the computer failed
to provide it and the dose was changed 11 % of the time
because the results were felt inaccurate. In addition, the
computer-advised appointment intervals were changed
by experienced clinicians 34 % of the time. More data is
needed to truly determine the impact of computer
assisted dosing in less experienced clinicians versus very
experienced clinicians/anticoagulation specialists.
Point of care testing by the patient or clinician allow
rapid determination of the INR without the need for a
centralized laboratory to acquire and analyze the sam-
ples. In a meta-analysis of 22 studies, including 4 studied
deemed of high methodological quality, the precision
and accuracy of the CoaguChek XS, INRatio, ProTime/
ProTime3, and Smartcheck INR coagulameter systems
were assessed [65]. The CoaguChek system was the most
commonly assed and yielded a coefficient of variation
that ranged from 1.4 to 5.9 and the concordance ranged
between 93 to 100 % showing congruence. The other
systems have coefficients of variation ranging from 3.7
to 8.4 and concordance values ranging from 81 to 97 %
(with the exception of one trial of the ProTime system
where the concordance was only 39 %. In general, point
of care testing is accurate and can facilitate patient
self-testing (where the patient self-tests the INR but
clinician doses) or patient self-management (where
the patient self-tests and self-adjusts VKA therapy
based on the INR.
In an 8-month open label crossover trial conducted in
Canadian primary care offices, patients (n = 11, 99
patient months, 122 INR determinations) underwent
patient self-management or physician management for
4 months [66]. Patients were trained and given an
algorithm to follow that specified the new dose and the
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timeframe for which to reassess the INR. The mean pro-
portion of INR values in therapeutic range among sub-
jects in the PSM and physician-management groups was
82 and 80 %, respectively (p = 0.82). Ten of the 11 pa-
tients preferred PSM to physician management and
elected to continue with this strategy after study com-
pletion (P = .001). No calls or visits were made to the
physician regarding dose adjustment during the pa-
tient self-management period. There were no episodes
of major bleeding or thromboembolic events. Studies
like this are promising but preliminary and it is un-
clear whether this is an effective therapy for highly
motivated and intelligent patients or patients with
health disparities or care barriers.
Conclusions
While experts recommend that patients spend at least
65 % of their TTR, this is seldom achieved or sustained
over time. A more common pattern – based on the
literature – is that there is high variability, and even the
patients who achieve target INR range do not remain in
this target range for long. Patients are more likely to
have INR below the therapeutic range, exposing them to
significant risk of adverse clinical events. Not achieving
a high TTR can result in thrombotic and major bleeding
events, inability to remain on therapy, and higher cost of
care. To avoid the adverse consequences of unstable
INR, careful evaluation of patients prior to initiating
therapy is important. Clinical prediction tools are avail-
able, though they can only explain <10 % of the variance
behind poor INR control because of the complex drivers
of genetic variation and patient medication adherence.
Clinicians caring for patients who require anticoagula-
tion are encouraged to apply intensified diligence in INR
management when using VKAs.
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